IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rick Strange who wrote (55)	10/16/1996 1:05:00 PM
From: Rudy Saucillo	of 305

Sounds like an interesting symposium. I would not anticipate any discussion of data from the ongoing Ragweed trial - mainly because, since it's such a relatively short trial, there's no reason to expend the resources to evaluate preliminary results. IMUL has stated that they will release the Phase III data on a similar schedule as the previous trial, i.e., in the late Feb. '97 timeframe. Regarding a new partnership, several analysts have speculated on which company would provide the best fit. I don't know that much about Connaught (other than the splash they've made with their DTaP vaccine) so can't really comment. IMUL has stated publicly that they may establish global and regional collaborations with several pharmaceuticals and expect to retain greater than the 50% share they had with HMR. They are also looking for a partner to fund development of allergy diagnostics and next generation, oral formulations of Allervax products. As we know, their target is to have these collaborations in place by the end of the first quarter next year. Cheers! Rudy (pardon the formatting; I still haven't figured out how to set paragraphs here...)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next